Financials SCHOTT Pharma AG & Co. KGaA

Equities

1SXP

DE000A3ENQ51

Medical Equipment, Supplies & Distribution

Real-time Estimate Tradegate 13:22:03 24/06/2024 BST 5-day change 1st Jan Change
26.37 EUR +0.27% Intraday chart for SCHOTT Pharma AG & Co. KGaA -4.16% -21.79%

Valuation

Fiscal Period: September 2023 2024 2025 2026
Capitalization 1 4,765 3,961 - -
Enterprise Value (EV) 1 4,914 4,162 4,149 4,091
P/E ratio 31.3 x 27.3 x 23.9 x 18.5 x
Yield 0.47% 0.59% 0.69% 0.86%
Capitalization / Revenue 5.3 x 4.06 x 3.6 x 3.17 x
EV / Revenue 5.47 x 4.26 x 3.77 x 3.27 x
EV / EBITDA 20.6 x 16.3 x 13.6 x 10.8 x
EV / FCF 491 x -301 x 144 x 58.1 x
FCF Yield 0.2% -0.33% 0.69% 1.72%
Price to Book 7.23 x 4.85 x 4.1 x 3.44 x
Nbr of stocks (in thousands) 150,615 150,615 - -
Reference price 2 31.64 26.30 26.30 26.30
Announcement Date 26/01/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2022 2023 2024 2025 2026
Net sales 1 821 898.6 976.5 1,100 1,250
EBITDA 1 219 239 256.1 305 377.8
EBIT 1 - 192.4 192 220.5 284.8
Operating Margin - 21.41% 19.66% 20.05% 22.79%
Earnings before Tax (EBT) 1 - 185.8 182.7 221.7 278.4
Net income 1 - 151.8 144.2 166.6 221.6
Net margin - 16.9% 14.76% 15.15% 17.73%
EPS 2 - 1.010 0.9651 1.099 1.421
Free Cash Flow 1 - 10 -13.84 28.76 70.35
FCF margin - 1.11% -1.42% 2.62% 5.63%
FCF Conversion (EBITDA) - 4.18% - 9.43% 18.62%
FCF Conversion (Net income) - 6.59% - 17.27% 31.75%
Dividend per Share 2 - 0.1500 0.1558 0.1820 0.2260
Announcement Date 26/01/23 26/01/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 228.5 232.3 234.3 222.9 287.3 - -
EBITDA 1 51.64 72.7 55.8 66.08 65.34 - -
EBIT 1 37.78 58.03 34.73 38.51 50.38 - -
Operating Margin 16.53% 24.99% 14.82% 17.27% 17.54% - -
Earnings before Tax (EBT) - - - - - - -
Net income 1 34.7 44.41 17.33 29.61 37.07 - -
Net margin 15.18% 19.12% 7.39% 13.28% 12.9% - -
EPS 2 0.2300 0.2900 0.2072 0.2030 0.2447 - -
Dividend per Share 2 - - - - 0.1570 - -
Announcement Date 26/01/24 01/03/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: September 2022 2023 2024 2025 2026
Net Debt 1 - 148 200 188 129
Net Cash position 1 - - - - -
Leverage (Debt/EBITDA) - 0.621 x 0.7827 x 0.6171 x 0.3427 x
Free Cash Flow 1 - 10 -13.8 28.8 70.4
ROE (net income / shareholders' equity) - 21.7% 19% 19.1% 20.2%
ROA (Net income/ Total Assets) - 12.5% 10.3% 11% 12.5%
Assets 1 - 1,214 1,393 1,519 1,767
Book Value Per Share 2 - 4.380 5.430 6.420 7.640
Cash Flow per Share 2 - 1.210 1.360 1.640 1.890
Capex 1 - 175 216 198 186
Capex / Sales - 19.53% 22.1% 18% 14.92%
Announcement Date 26/01/23 26/01/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
11
Last Close Price
26.3 EUR
Average target price
34.84 EUR
Spread / Average Target
+32.46%
Consensus
  1. Stock Market
  2. Equities
  3. 1SXP Stock
  4. Financials SCHOTT Pharma AG & Co. KGaA